DM
OKUR

Deerfield Management’s OnKure Therapeutics OKUR Stock Holding History

Deerfield Management’s Portfolio OKUR Stock Details OKUR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-84,930
Closed -$6.33M – 144
2021
Q3 		$6.33M Hold
84,930
– – 0.12% 108
2021
Q2 		$7.92M Buy
+84,930
New +$9.47M 0.14% 119

Other funds holding OKUR

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
RVM
RiverVest Venture Management St. Louis, Missouri $6.84M AUM 7.71% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Deerfield Management's OKUR Position: Q4 2021 in Review

Deerfield Management sold out of OnKure Therapeutics (OKUR) in Q4 2021, closing a stake of 84,930 shares — an estimated $6.33M sold.

Deerfield Management first reported a position in OKUR in Q2 2021 and held it in 2 quarters. The position peaked at $7.92M in Q2 2021. 39 funds tracked by Wall St. Rank hold OKUR as of Q4 2021.

  • Deerfield Management reported no remaining OnKure Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Deerfield Management sold 84,930 OnKure Therapeutics shares in Q4 2021, an estimated $6.33M.
  • Deerfield Management first reported a position in OnKure Therapeutics in Q2 2021 and held it in 2 quarters.
  • Deerfield Management's OnKure Therapeutics position peaked at $7.92M in Q2 2021.
  • 39 funds tracked by Wall St. Rank held OnKure Therapeutics as of Q4 2021.

Based on Deerfield Management's 13F filing for Q4 2021, filed 14 Feb 2022.